論文・技術情報追加のお知らせ

1. Epidemiologic investigation on neurological complications following neuraxial anesthesia in 2.7 million cases in Southwest China.

中国で硬膜外麻酔後の神経障害は0.44件/千人

対象DB：FAERS

2. Real-World pharmacovigilance analysis of drug-related conjunctivitis using the FDA adverse event reporting system database.

トラロキヌマブなどで結膜炎リスク上昇

対象DB：FAERS

3. Re-assessing the risk-benefit profile of Thiazolidinediones: Cardiovascular Risks and Stroke Prevention Through Real-World Data.

ロシグリタゾンは心血管リスク高、ピオは低

対象DB：FAERS

4. Emerging and Established Adverse Events of Pasireotide: A Twelve-Year Pharmacovigilance Study.

パシレオチドで高血糖等に加え新規有害事象も判明

対象DB：FAERS

5. Comparative safety analysis of baloxavir marboxil and oseltamivir based on the FAERS database.

オセルタミビルとバロキサビルでの新たな有害事象に注意

対象DB：FAERS

6. Infection-related adverse events comparison of Bortezomib, Carfilzomib and Ixazomib:A pharmacovigilance study based on FAERS.

PIsは感染関連有害事象に注意が必要

対象DB：FAERS

7. A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemab.

レカネマブは脳出血等の重篤副作用に注意

対象DB：FAERS

8. Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data.

GLP-1薬と男性性機能障害の関連弱い

対象DB：FAERS

9. A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database.

オマダサイクリンで新たな重篤副作用発見

対象DB：FAERS

10. Variations in adverse events associated with different infusion modalities of parenteral nutrition: A pharmacovigilance study.

異なる栄養注入法で副作用に差異

対象DB：FAERS

11. Adverse events of concomitant use of immune checkpoint inhibitors and metformin or statin: an observational, retrospective disproportionality analysis.

ICIとメトホルミン・スタチン併用で重篤な副作用

対象DB：FAERS

12. A disproportionality analysis of interstitial lung disease associated with drug therapy in spontaneous adverse event reports.

薬剤による間質性肺疾患のリスクが明らかに

対象DB：FAERS

13. Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system.

リプレチニブの副作用には皮膚癌や肝膿瘍が新たに確認された

対象DB：FAERS

14. Comparing drug combinations for graft-versus-host disease prophylaxis using the U.S. Food and Drug Administration Adverse Event Reporting System.

GVHD予防薬の組み合わせにおいて、シクロスポリンを含むものが効果的な場合がある

対象DB：FAERS

15. A real-world pharmacovigilance study and pharmacological analysis of sulfasalazine based on the FDA adverse event reporting system (FAERS) database.

サルファサラジンの副作用として新たな兆候が発見され、さらなる確認が必要

対象DB：FAERS

16. Safety profile of faricimab: a multi-source pharmacovigilance analysis using FAERS and JADER.

ファリシマブは眼疾患治療薬で新たなシグナルが報告

対象DB：FAERS,JADER

17. Drug-induced Guillain-Barre Syndrome: a disproportionality analysis based on the US FDA adverse event reporting system.

薬剤によるギラン・バレー症候群（GBS）は免疫関連薬で多く発生

対象DB：FAERS,VAERS

18. Comprehensive analysis of adverse drug reactions associated with teduglutide: post-marketing insights and safety implications.

テドグルチドは、SBS治療で重篤な副作用を引き起こす

対象DB：FAERS

19. Hepatobiliary disorders and Direct-Acting Antiviral (DAA) therapies: real-world evidence and insights from the EudraVigilance database.

ハーボニーは肝胆道障害の報告頻度が低い

対象DB：EudraVigilance

20. Risk Management of Medication Errors: Improving the Quality of Pharmacotherapeutic Practice.

薬剤治療の品質改善に向けた戦略分析

対象DB：EudraVigilance

21. Hypogammaglobulinemia in patients with multiple sclerosis receiving disease modifying therapies: disproportionality analysis using the EudraVigilance database.

抗CD20モノクローナル抗体は多発性硬化症患者で低ガンマグロブリン血症や感染症リスクを高める

対象DB：EudraVigilance

22. Incidence of Myocarditis Caused by Drugs Used for Ulcerative Colitis as Examined Using VigiBase, a Spontaneous Adverse Drug Reaction Reporting Database.

メサラジンは年齢や性別に関わらず心筋炎のリスクが示唆される

対象DB：VigiBase

23. Investigating Risk of Cancer with Sodium-Glucose Cotransporter 2 Inhibitors: A Disproportionality Analysis in the WHO Global Pharmacovigilance Database Vigibase((R)).

SGLT-2阻害薬は膀胱・腎がん報告が多い

対象DB：VigiBase

24. Evaluation of pregabalin-induced oedema using the adverse event spontaneous reporting database and the prescription claims database.

プレガバリンは初期に浮腫を起こしやすい

対象DB：JADER

25. Factors associated with regional differences in healthcare quality for patients with acute myocardial infarction in Japan.

高齢化率や医療資源がAMI治療の地域差に影響

対象DB：DPC

26. Comparison of diffusion-weighted whole-body magnetic resonance imaging and abdominal ultrasonography versus contrast-enhanced computed tomography in diagnosing acute focal bacterial nephritis: a retrospective cohort study.

DWIBSは腹部超音波よりAFBN診断精度が高く、CT不可患者に有用

対象DB：DPC

27. Incidence, prevalence, and mortality of sarcoidosis in England: a population-based study.

イギリスでサルコイドーシスの有病率と死亡率が上昇

対象DB：CPRD

28. Primary Care and Linked Secondary Care Encounters for Foot and Ankle Problems in Children and Young People: A Population-Based Cohort Study in England.

足首・足の問題で、若年層に人種差があり、紹介が不平等

対象DB：CPRD

29. Mineralocorticoid receptor antagonist (MRA) use in UK heart failure care: a national primary care cohort study.

HFrEF患者でMRAは依然として過少使用

対象DB：THIN

30. Prescription patterns of comedications associated with drug-drug interactions risk in HCV-infected patients undergoing direct-acting antiviral treatment: an analysis of an administrative claims database in Japan.

DAA治療中にDDIリスクの併用薬多い

対象DB：DeSC

31. Adverse events, including fractures, among older patients receiving mirogabalin versus pregabalin: A retrospective cohort study using a large claims database in Japan.

ミロガバリンは転倒骨折リスクが僅かに低い

対象DB：DeSC

32. DeSC database.

DeSC使用研究は増加中も未開拓領域多い

対象DB：DeSC